BioHelix’ isothermal-amplification technology will be leveraged.

Quidel will be developing in vitro molecular diagnostic tests utilizing BioHelix’ isothermal-amplification technology. BioHelix’ expertise in the R&D of nucleic acid technologies for diagnostic applications will be combined with Quidel’s strength in the development, manufacture, and commercialization of such tests.

Under the development and commercialization agreement, Quidel will fund and jointly develop with BioHelix assays for rapid detection of infectious pathogens in a noninstrumented, handheld format. BioHelix will have primary responsibility for assay development. Quidel will have exclusive, worldwide commercialization rights for the new products. It will also undertake all manufacturing and marketing.

BioHelix’ IsoAmp® Molecular Analyzer is an instrument-free molecular diagnostic platform consisting of its Helicase-Dependent Amplification technology and a disposable detection device entitled the BESt™ Cassette.

Previous articleWhile Grateful for Recovery Act Funds, Experts Stress the Importance of Continued Robust Funding
Next articleRussian Stem Cell Company Hopes to Raise Roughly $5.54M through IPO on Moscow Stock Exchange